15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Familial globular glial tauopathy linked to MAPT mutations: molecular neuropathology and seeding capacity of a prototypical mixed neuronal and glial tauopathy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Globular glial tauopathy (GGT) is a progressive neurodegenerative disease involving the grey matter and white matter (WM) and characterized by neuronal deposition of hyper-phosphorylated, abnormally conformed, truncated, oligomeric 4Rtau in neurons and in glial cells forming typical globular astrocyte and oligodendrocyte inclusions (GAIs and GOIs, respectively) and coiled bodies. Present studies centre on four genetic GGT cases from two unrelated families bearing the P301T mutation in MAPT and one case of sporadic GGT (sGGT) and one case of GGT linked to MAPT K317M mutation, for comparative purposes. Clinical and neuropathological manifestations and biochemical profiles of phospho-tau are subjected to individual variations in patients carrying the same mutation, even in carriers of the same family, independently of the age of onset, gender, and duration of the disease. Immunohistochemistry, western blotting, transcriptomic, proteomics and phosphoproteomics, and intra-cerebral inoculation of brain homogenates to wild-type (WT) mice were the methods employed. In GGT cases linked to MAPT P301T mutation, astrocyte markers GFAP, ALDH1L1, YKL40 mRNA and protein, GJA1 mRNA, and AQ4 protein are significantly increased; glutamate transporter GLT1 (EAAT2) and glucose transporter (SLC2A1) decreased; mitochondrial pyruvate carrier 1 (MPC1) increased, and mitochondrial uncoupling protein 5 (UCP5) almost absent in GAIs in frontal cortex (FC). Expression of oligodendrocyte markers OLIG1 and OLIG2 mRNA, and myelin-related genes MBP, PLP1, CNP, MAG, MAL, MOG, and MOBP are significantly decreased in WM; CNPase, PLP1, and MBP antibodies reveal reduction and disruption of myelinated fibres; and SMI31 antibodies mark axonal damage in the WM. Altered expression of AQ4, GLUC-t, and GLT-1 is also observed in sGGT and in GGT linked to MAPT K317M mutation. These alterations point to primary astrogliopathy and oligodendrogliopathy in GGT. In addition, GGT linked to MAPT P301T mutation proteotypes unveil a proteostatic imbalance due to widespread (phospho)proteomic dearrangement in the FC and WM, triggering a disruption of neuron projection morphogenesis and synaptic transmission. Identification of hyper-phosphorylation of variegated proteins calls into question the concept of phospho-tau-only alteration in the pathogenesis of GGT. Finally, unilateral inoculation of sarkosyl-insoluble fractions of GGT homogenates from GGT linked to MAPT P301T, sGGT, and GGT linked to MAPT K317M mutation in the hippocampus, corpus callosum, or caudate/putamen in wild-type mice produces seeding, and time- and region-dependent spreading of phosphorylated, non-oligomeric, and non-truncated 4Rtau and 3Rtau, without GAIs and GOIs but only of coiled bodies. These experiments prove that host tau strains are important in the modulation of cellular vulnerability and phenotypes of phospho-tau aggregates.

          Electronic supplementary material

          The online version of this article (10.1007/s00401-019-02122-9) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references92

          • Record: found
          • Abstract: found
          • Article: not found

          Astrocyte dysfunction in neurological disorders: a molecular perspective.

          Recent work on glial cell physiology has revealed that glial cells, and astrocytes in particular, are much more actively involved in brain information processing than previously thought. This finding has stimulated the view that the active brain should no longer be regarded solely as a network of neuronal contacts, but instead as a circuit of integrated, interactive neurons and glial cells. Consequently, glial cells could also have as yet unexpected roles in the diseased brain. An improved understanding of astrocyte biology and heterogeneity and the involvement of these cells in pathogenesis offers the potential for developing novel strategies to treat neurological disorders.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Connexins, connexons, and intercellular communication.

            Cells in tissues share ions, second messengers, and small metabolites through clusters of intercellular channels called gap junctions. This type of intercellular communication permits coordinated cellular activity. Intercellular channels are formed from two oligomeric integral membrane protein assemblies, called connexons, which span two adjacent cells' plasma membranes and join in a narrow, extracellular "gap." Connexons are formed from connexins, a highly related multigene family consisting of at least 13 members. Since the cloning of the first connexin in 1986, considerable progress has been made in our understanding of the complex molecular switches that control the formation and permeability of the intercellular channels. Analysis of the mechanisms of channel assembly has revealed the selectivity of inter-connexin interactions and uncovered novel characteristics of the channel permeability and gating behavior. Structure-function studies provide a molecular understanding of the significance of connexin diversity and demonstrate the unique regulation of connexins by tyrosine kinases and oncogenes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain.

              Astrocyte pathology occurs in association with Alzheimer's disease (AD) and in brain ageing, but is poorly characterised. We sought to define the detailed cellular pathology of astrocytes, the extent of population variation and the relationship to Alzheimer-type changes in a population-based cohort. Three staining patterns were associated with GFAP and excitatory amino acid transporter 2 (EAAT2): minimal, moderate or extensive immunoreactivity. GFAP and EAAT2 expression were inversely related (p=0.015), with trends to increased expression of GFAP (p=0.019) and decreased expression of EAAT2 (p=ns) with increasing Braak stage. GFAP and EAAT2 correlated incompletely with beta-amyloid and tau immunoreactivity. However, gliosis increased with increasing burden of neuritic (p=0.011), but not diffuse (p=ns), plaques. Double-staining revealed distinct subsets of astrocytes; GFAP(+)EAAT(-), GFAP(-)EAAT(+), or GFAP(+)EAAT(+). In contrast to the variation in GFAP and EAAT2, levels of EAAT1 and S100B showed consistent staining patterns. Alzheimer-type pathology only partially explains the variation in gliosis and astrocyte functional markers, suggesting that other factors contribute to the population variance in astrocyte pathology. Copyright (c) 2008 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                8082ifa@gmail.com
                Journal
                Acta Neuropathol
                Acta Neuropathol
                Acta Neuropathologica
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0001-6322
                1432-0533
                6 January 2020
                6 January 2020
                2020
                : 139
                : 4
                : 735-771
                Affiliations
                [1 ]GRID grid.5841.8, ISNI 0000 0004 1937 0247, Department of Pathology and Experimental Therapeutics, , University of Barcelona, ; Feixa Llarga sn, 08907 Hospitalet de Llobregat, Spain
                [2 ]GRID grid.411129.e, ISNI 0000 0000 8836 0780, Bellvitge University Hospital, ; Hospitalet de Llobregat, Spain
                [3 ]GRID grid.413448.e, ISNI 0000 0000 9314 1427, CIBERNED (Network Centre of Biomedical Research of Neurodegenerative Diseases), Ministry of Economy and Competitiveness, , Institute of Health Carlos III, ; Madrid, Spain
                [4 ]GRID grid.5841.8, ISNI 0000 0004 1937 0247, Institute of Neurosciences, , University of Barcelona, ; Barcelona, Spain
                [5 ]GRID grid.418284.3, ISNI 0000 0004 0427 2257, Bellvitge Biomedical Research Institute (IDIBELL), ; Hospitalet de Llobregat, Barcelona, Spain
                [6 ]GRID grid.411730.0, ISNI 0000 0001 2191 685X, Pathological Anatomy Department, , Hospital of Navarra, ; Pamplona, Spain
                [7 ]GRID grid.497559.3, Neurology Department, , Complejo Hospitalario de Navarra, ; Pamplona, Spain
                [8 ]Clinical Neuroproteomics Laboratory, Proteomics Unit, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA, Proteored-ISCIII, NavarrabiomedPamplona, Spain
                [9 ]GRID grid.473715.3, Molecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Science Park Barcelona (PCB), , Barcelona Institute for Science and Technology, ; Barcelona, Spain
                [10 ]GRID grid.5841.8, ISNI 0000 0004 1937 0247, Department of Cell Biology, Physiology and Immunology, Faculty of Biology, , University of Barcelona, ; Barcelona, Spain
                Author information
                http://orcid.org/0000-0001-9888-8754
                Article
                2122
                10.1007/s00401-019-02122-9
                7096369
                31907603
                2cfeab82-957b-4852-b473-0afa3973d218
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 21 October 2019
                : 23 December 2019
                : 23 December 2019
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100010434, “la Caixa” Foundation;
                Award ID: LCF/PR/HR19/52160007
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100004587, Instituto de Salud Carlos III;
                Award ID: FIS PI17/000809
                Award Recipient :
                Funded by: ERDF
                Award ID: RedPrion 148/16
                Award Recipient :
                Categories
                Original Paper
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2020

                Neurology
                globular glial tauopathy,tau,astrogliopathy,oligodendrogliopathy,phosphoproteome,seeding and spreading

                Comments

                Comment on this article